XDS-23

XDS-23 (0.3125-5 μM, 24 h) inhibits biofilm formation in P. aeruginosa PAO1, reducing biofilm biomass by up to 60 % (at 5 µM), diminishing viable cell counts within the biofilm without affecting planktonic growth, and concurrently suppressing exopolysaccharide (EPS) synthesis by 50% at the same concentration, ultimately leading to thinner and structurally disrupted biofilms^[1].
XDS-23 (0.3125-5 μM, 20 and 24 h) inhibits pyocyanin and elastase production in a concentration-dependent manner, resulting in a significant inhibition of 70 % and 50 % at 5 μM, respectively, in P. aeruginosa PAO1^[1].
XDS-23 (0.3125-5 μM, 24 h) demonstrates broad-spectrum activity against clinically resistant P. aeruginosa isolates, achieving significant inhibition in multiple strains, including nearly 50% inhibition in PA0617 and PA1065, and 44.87%, 34.89%, 33.56%, and 36.80% inhibition in PA0808, PA1129, PA1074, and PA1167, respectively^[1].
XDS-23 (0.3125-5 μM, 20 h) decreases the secretion of pyocyanin in all clinical isolates of P.aeruginosa except PA1031, for PA0808, PA0617, and PA1074, it resulted in exceeding 30 % inhibition^[1].
XDS-23 (0.3125-5 μM, 24 h) reduces biofilm formation and virulence primarily by inhibiting the las and pqs systems in P. aeruginosa PAO1^[1].
XDS-23 (5 μM, 24 h) concentration-dependently suppresses motilities of P. Aeruginosa, inhibiting swarming (by 60% at 5 μM), inhibiting twitching (by 50%), and attenuating swimming (by 30%)^[1].
XDS-23 (0.3125-5 μM, 24 h) reduces the bacterial load when co-administered with Polymyxin B (PMB) (HY-149179), Ciprofloxacin (CIP) (HY-B0356), Ceftazidime (CAZ) (HY-B0593), and Tobramycin (Tob) (HY-B0441) in P. aeruginosa PAO1 ^[1].
XDS-23 (6.25-100 μM, 24 h) has no significant cytotoxicity in human hepatocyte-derived HepG2 cells^[1].
XDS-23 (1.25-40 μM, 4 h) exhibits negligible hemolytic activity against rabbit erythrocytes^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.